Medicare Enrolled
Dr. Rebecca Barrington, M.D.
Medical Oncology · Kerrville, TX
Practice pattern: Mixed Practice— Diverse clinical practice across multiple procedure types
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Barrington from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Barrington? Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Barrington
Dr. Rebecca Barrington is a medical oncology in Kerrville, TX, with 19 years in practice. Based on federal Medicare data, Dr. Barrington performed 104,730 Medicare services across 6,682 unique beneficiaries.
Between the years covered by Open Payments, Dr. Barrington received a total of $1,682 from 34 pharmaceutical and/or device companies across 95 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in medical oncology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Barrington is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 19 years in practice▲ Top 9% volume in TX$ $1,682 industry payments
Medicare Practice Summary
Medicare Utilization ↗104,730
Medicare services
Top 9% in TX for medical oncology
6,682
Unique beneficiaries
$11
Avg. Medicare payment
Medicare patients only (65+ / disabled) · Not a quality rating · How to read this →
~5,512 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Iron infusion (Feraheme) | 42,330 | $0 | $5 |
| Pembrolizumab injection (Keytruda) | 16,500 | $43 | $137 |
| Anti-nausea injection (fosaprepitant) | 14,850 | $0 | $5 |
| Paclitaxel chemotherapy injection | 7,896 | $0 | $8 |
| Dexamethasone injection (steroid) | 2,113 | $0 | $1 |
| Blood draw (venipuncture) | 1,833 | $8 | $20 |
| Complete blood count (CBC) with differential | 1,822 | $8 | $36 |
| Anti-nausea injection (Aloxi/palonosetron) | 1,430 | $1 | $114 |
| Lactate dehydrogenase (enzyme) level | 1,306 | $6 | $31 |
| Uric acid level test | 1,292 | $4 | $25 |
| Comprehensive metabolic blood panel | 1,280 | $10 | $64 |
| Injection, granisetron hydrochloride, 100 mcg | 1,210 | $0 | $24 |
| Injection, sodium ferric gluconate complex in sucrose injection, 12.5 mg | 1,080 | $2 | $16 |
| Flow cytometry, additional marker | 647 | $18 | $180 |
| Office visit, established patient (30-39 min) | 637 | $92 | $368 |
| Carcinoembryonic antigen (cea) protein level | 574 | $19 | $99 |
| Administration of chemotherapy into vein, 1 hour or less | 499 | $98 | $707 |
| Infusion, normal saline solution , 1000 cc | 487 | $2 | $19 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 466 | $22 | $157 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 431 | $47 | $313 |
| Injection, carboplatin, 50 mg | 421 | $2 | $300 |
| Basic metabolic blood panel | 409 | $8 | $49 |
| Immunologic analysis for detection of tumor antigen, quantitative; ca 15-3 | 342 | $20 | $128 |
| Ferritin level test (iron stores) | 314 | $13 | $60 |
| Iron level test | 314 | $6 | $27 |
| Iron binding capacity test | 313 | $9 | $35 |
| Microscopic examination for white blood cells with manual cell count | 289 | $4 | $22 |
| Complete blood count (CBC), automated | 289 | $6 | $34 |
| Infusion into a vein for hydration, 31-60 minutes | 245 | $23 | $256 |
| Office visit, established patient (20-29 min) | 243 | $59 | $250 |
| Infusion into a vein for hydration, each additional hour | 202 | $10 | $75 |
| Beta-2 microglobulin (protein) level | 195 | $16 | $96 |
| Measurement of immunoglobulin light chains | 182 | $17 | $60 |
| Administration of additional new drug or substance into vein, 1 hour or less | 173 | $49 | $344 |
| Administration of chemotherapy into vein, each additional hour | 159 | $21 | $161 |
| Immunoglobulin level test | 158 | $9 | $56 |
| Drug injection, under skin or into muscle | 150 | $10 | $96 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 130 | $16 | $100 |
| Reticulated (young) platelet measurement | 128 | $35 | $143 |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 108 | $53 | $211 |
| Thyroid stimulating hormone (TSH) test | 104 | $16 | $80 |
| Injection, diphenhydramine hcl, up to 50 mg | 93 | $1 | $7 |
| Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 92 | $90 | $657 |
| New patient office visit (45-59 min) | 78 | $119 | $565 |
| Nuclear medicine study from skull base to mid-thigh with ct scan | 75 | $1,106 | $4,802 |
| Thyroxine (thyroid chemical), total | 75 | $7 | $32 |
| Prothrombin time test (blood clotting) | 66 | $4 | $30 |
| Magnesium level test | 62 | $7 | $29 |
| Immunologic analysis for detection of tumor antigen, quantitative; ca 19-9 | 57 | $20 | $128 |
| Unclassified drugs | 52 | $1 | $8 |
| Immunologic analysis for detection of tumor antigen, quantitative; ca 125 | 50 | $20 | $128 |
| Red blood count automated, with additional calculations | 47 | $5 | $26 |
| Injection of additional new drug or substance into vein | 45 | $12 | $108 |
| Drawing of blood for a medical problem | 41 | $65 | $264 |
| Office visit, established patient, complex (40-54 min) | 41 | $130 | $496 |
| Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion | 39 | $15 | $94 |
| Administration of additional new drug or substance into vein using push technique | 36 | $42 | $289 |
| PSA test (prostate cancer screening) | 34 | $18 | $94 |
| Vitamin B-12 level test | 33 | $15 | $76 |
| Liver function blood test panel | 32 | $8 | $48 |
| Flow cytometry technique for dna or cell analysis, first marker | 28 | $50 | $298 |
| Irrigation of implanted venous access drug delivery device | 22 | $18 | $114 |
| Nuclear medicine study whole body with ct scan | 17 | $1,079 | $4,929 |
| Urinalysis with microscopic exam | 16 | $3 | $28 |
| Folic acid level test | 16 | $14 | $73 |
| Protein measurement, serum | 16 | $11 | $99 |
| Immunologic analysis technique on serum (immunofixation) | 16 | $22 | $160 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
42.3% high complexity
44.5% medium
13.1% routine
Industry Payment Transparency
Open Payments through 2024 ↗$1,682
Total received (2018-2024)
Avg $240/year across 7 years
Bottom 35% in TX for medical oncology
34
Companies
95
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$1,358 (80.7%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$324 (19.3%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024$93
2023$47
2022$263
2021$336
2020$289
2019$366
2018$288
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
PFIZER INC.
$353
Janssen Biotech, Inc.
$220
E.R. Squibb & Sons, L.L.C.
$115
Takeda Pharmaceuticals U.S.A., Inc.
$99
Amgen Inc.
$85
Incyte Corporation
$61
PUMA BIOTECHNOLOGY, INC.
$59
GENZYME CORPORATION
$59
Novartis Pharmaceuticals Corporation
$56
AstraZeneca Pharmaceuticals LP
$51
Eisai Inc.
$46
ADC Therapeutics America, Inc.
$37
Boehringer Ingelheim Pharmaceuticals, Inc.
$35
BeiGene USA, Inc.
$33
Puma Biotechnology, Inc.
$31
Lilly USA, LLC
$29
JAZZ PHARMACEUTICALS INC.
$26
Sobi, Inc
$25
Karyopharm Therapeutics Inc.
$24
Ipsen Biopharmaceuticals, Inc
$23
Myriad Genetic Laboratories, Inc.
$20
EMD Serono, Inc.
$19
Rigel Pharmaceuticals, Inc.
$18
Celgene Corporation
$17
EISAI INC.
$17
Regeneron Healthcare Solutions, Inc.
$17
Kite Pharma, Inc.
$16
Genentech USA, Inc.
$15
Merck Sharp & Dohme Corporation
$15
Array BioPharma Inc.
$14
APTEVO THERAPEUTICS INC
$12
Acrotech Biopharma LLC
$12
Gilead Sciences, Inc.
$12
Seattle Genetics, Inc.
$11
Top 3 companies account for 40.9% of total payments
Associated products mentioned in payments ›
ADCETRIS · ALIMTA · Alecensa · BELEODAQ · BOSULIF · BRUKINSA · Bavencio · Braftovi · CYRAMZA · DARZALEX · DOPTELET · ELIQUIS · ELITEK · ERLEADA · Erleada · GILOTRIF · Halaven · IBRANCE · IXINITY · JADENU · JEVTANA · KISQALI · Kyprolis · LENVIMA · LIBTAYO · Lenvima · MYLOTARG · NERLYNX · Nerlynx · Nplate · OPDIVO · REBLOZYL · SARCLISA · Somatuline Depot · TAGRISSO · TASIGNA · Tavalisse · VOTRIENT · XPOVIO · XTANDI · ZEPZELCA · myChoice CDx
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (81%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Equivalent to $2 per 100 Medicare services performed
Geographic Context
Medical Oncologys within 10 mi
1
Per 100K population
1.9
County median income
$67,927
Nearest hospital
PETERSON REGIONAL MEDICAL CENTER
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →
Summary
Dr. Barrington is a mixed practice specialist, with above-average Medicare volume (top 9% in TX), and low-engagement industry engagement, with 19 years of practice experience.
This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →
Frequently Asked Questions
Is Dr. Barrington experienced with iron infusion (feraheme)?
Based on Medicare claims data, Dr. Barrington performed 42,330 iron infusion (feraheme) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Barrington receive payments from pharmaceutical companies?
Yes. Dr. Barrington received a total of $1,682 from 34 companies across 95 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Barrington's costs compare to other medical oncologys in Kerrville?
Dr. Barrington's average Medicare payment per service is $11. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Barrington) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Medical Oncologys in Kerrville
Browse medical oncologys in Kerrville ranked by procedure volume and transparency data.
Highest volume
Top Medical Oncologys in TX
Medical Oncologys ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Medical Oncologys in TX
Which TX medical oncologys receive the most from drug and device companies.
By company
PFIZER INC. Payments to Doctors
See all physicians who received payments from PFIZER INC..
By company
Janssen Biotech, Inc. Payments to Doctors
See all physicians who received payments from Janssen Biotech, Inc..
By company
E.R. Squibb & Sons, L.L.C. Payments to Doctors
See all physicians who received payments from E.R. Squibb & Sons, L.L.C..
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology